Fiscal year 2024 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses INZY in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named INZY in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Douglas Treco | $541,667 | $0 | $0 | $1,933,375 | $0 | $0 | $10,350 | $2,485,392 |
| Chief Executive Officer and Chairman | ||||||||
| Matthew Winton | 456,750 | 0 | 1,162,799 | 0 | 135,000 | 0 | 10,350 | 1,764,899 |
| Senior Vice President and Chief Operating Officer | ||||||||
| Sanjay Subramanian | 462,033 | 0 | 0 | 1,096,354 | 135,000 | 0 | 10,350 | 1,703,737 |
| Senior Vice President and Chief Financial Officer and Head of Business Development | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Douglas Treco | $2,485,392 | $5,299,476 | — | −2,814,084 |
| Matthew Winton | 1,764,899 | 1,548,627 | — | +216,272 |
| Sanjay Subramanian | 1,703,737 | 1,032,937 | — | +670,800 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Douglas Treco | Option | — | — | — | — | — | $1,933,375 |
| Matthew Winton | RSU | — | — | — | — | — | 1,162,799 |
| Sanjay Subramanian | Option | — | — | — | — | — | 1,096,354 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Douglas Treco | $0 | $0 | $1,933,375 | 0.0% |
| Matthew Winton | 1,162,799 | 0 | 0 | 0.0% |
| Sanjay Subramanian | 0 | 0 | 1,096,354 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Douglas Treco | Option | 243,750 | 5.77 | — |
| Douglas Treco | RSU | 75,000 | — | 207,750 |
| Sanjay Subramanian | Option | 56,250 | 3.96 | — |
| Douglas Treco | Option | 466,667 | 5.73 | — |
| Sanjay Subramanian | Option | 75,938 | 3.3 | — |
| Sanjay Subramanian | Option | 134,063 | 5.77 | — |
| Matthew Winton | Option | 145,834 | 5.39 | — |
| Matthew Winton | Option | 142,188 | 5.77 | — |
We use base compensation or salaries to recognize the experience, skills, knowledge and responsibilities required of our executive officers. Performance-based bonuses, which are calculated as a percentage of base salary, are designed to motivate our executive officers to achieve annual goals based on our strategic, financial and operating performance objectives. Although we do not have a formal policy with respect to the grant of equity incentive awards to our executive officers, or any formal equity ownership guidelines applicable to them, we believe that equity grants provide our executive officers with a strong link to our long-term performance, create an ownership culture and help to align the interests of our executive officers and our stockholders.
| CEO STI target (% of salary) | 55% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Erik HarrisIndependent · Newly elected | $9,783 | $0 | $272,503 | — | $0 | $282,286 |
| Reinaldo DiazIndependent · Lead Independent Director · Compensation (Chair) | 68,125 | 0 | 123,200 | — | 0 | 191,325 |
| Martin EdwardsIndependent · Audit · Nominating/Governance (Chair) · Research and Development (Chair) | 62,250 | 0 | 123,200 | — | 0 | 185,450 |
| Lynne SullivanIndependent · Audit (Chair) | 53,750 | 0 | 123,200 | — | 0 | 176,950 |
| Sarah BhagatIndependent · Audit | 48,766 | 0 | 123,200 | — | 0 | 171,966 |
| Edward MathersIndependent · Compensation · Nominating/Governance | 47,750 | 0 | 123,200 | — | 0 | 170,950 |
| Robert HopfnerIndependent · Compensation | 43,750 | 0 | 123,200 | — | 0 | 166,950 |
| Axel BolteNot independent · Research and Development | 40,893 | 0 | 123,200 | — | 0 | 164,093 |
| Douglas A. TrecoEmployee director · Board Chair · Research and Development | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $123,200 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 7,500 / 5,000 / 4,000 |
| Stock ownership guideline | — |
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $375,067 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $375,067 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Inozyme Pharma | 2024 | Douglas Treco | $541,667 | $0 | $1,933,375 | $0 | $2,485,392 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Douglas Treco | DEF 14A | 2025-04-29 | 0000950170-25-060198 | Section “Summary Compensation Table”. As printed: 2,485,392. Filing ↗machine: span 345346–345355 |
| 2 | Section 01, Matthew Winton | DEF 14A | 2025-04-29 | 0000950170-25-060198 | Section “Summary Compensation Table”. As printed: 1,764,899. Filing ↗machine: r6 · c22 · span 377932–377941 |
| 3 | Section 01, Sanjay Subramanian | DEF 14A | 2025-04-29 | 0000950170-25-060198 | Section “Summary Compensation Table”. As printed: 1,703,737. Filing ↗machine: r4 · c22 · span 361577–361586 |
| 4 | Section 03, Douglas Treco Option | DEF 14A | 2025-04-29 | 0000950170-25-060198 | Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t4 · r2 · c13 · span 341998–342007 |
| 5 | Section 03, Matthew Winton RSU | DEF 14A | 2025-04-29 | 0000950170-25-060198 | Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t4 · r6 · c13 · span 374595–374604 |
| 6 | Section 03, Sanjay Subramanian Option | DEF 14A | 2025-04-29 | 0000950170-25-060198 | Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t4 · r4 · c13 · span 358267–358276 |
| 7 | Section 08, Erik Harris | DEF 14A | 2025-04-29 | 0000950170-25-060198 | Section “Director Compensation”. As printed: 282,286. Filing ↗machine: t8 · r6 · c10 · span 744407–744414 |
| 8 | Section 08, Reinaldo Diaz | DEF 14A | 2025-04-29 | 0000950170-25-060198 | Section “Director Compensation”. As printed: 191,325. Filing ↗machine: t8 · r4 · c10 · span 735535–735542 |
| 9 | Section 08, Martin Edwards | DEF 14A | 2025-04-29 | 0000950170-25-060198 | Section “Director Compensation”. As printed: 185,450. Filing ↗machine: t8 · r5 · c10 · span 740032–740039 |
| 10 | Section 08, Lynne Sullivan | DEF 14A | 2025-04-29 | 0000950170-25-060198 | Section “Director Compensation”. As printed: 176,950. Filing ↗machine: t8 · r9 · c10 · span 757914–757921 |
| 11 | Section 08, Sarah Bhagat | DEF 14A | 2025-04-29 | 0000950170-25-060198 | Section “Director Compensation”. As printed: 171,966. Filing ↗machine: t8 · r2 · c10 · span 726575–726582 |
| 12 | Section 08, Edward Mathers | DEF 14A | 2025-04-29 | 0000950170-25-060198 | Section “Director Compensation”. As printed: 170,950. Filing ↗machine: t8 · r8 · c10 · span 753417–753424 |
| 13 | Section 08, Robert Hopfner | DEF 14A | 2025-04-29 | 0000950170-25-060198 | Section “Director Compensation”. As printed: 166,950. Filing ↗machine: t8 · r7 · c10 · span 748895–748902 |
| 14 | Section 08, Axel Bolte | DEF 14A | 2025-04-29 | 0000950170-25-060198 | Section “Director Compensation”. As printed: 164,093. Filing ↗machine: t8 · r3 · c10 · span 731023–731030 |
| 15 | Section 08, Douglas A. Treco | DEF 14A | 2025-04-29 | 0000950170-25-060198 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 16 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 17 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 18 | Section 09b board cost (computed) | Computed | — | computed | Cash 375,067 + equity 0 + all other 0 = 375,067, summed across the director compensation table rows.machine: formula: Σ = 375,067 |
| 19 | Inozyme Pharma (subject), Section 10b CEO total | DEF 14A | 2025-04-29 | 0000950170-25-060198 | CEO total compensation as printed in Inozyme Pharma's own proxy. As printed: 2,485,392. Filing ↗machine: span 345346–345355 |